It’s tough, watching this play out slowly, step by painful step. As I’ve blogged before, ME/CFS consumer advocates have been hammering away to get this Cochrane systematic review on exercise and CFS fundamentally
Am I Going to Need a Smaller Plate? In Which I Juggle a New Weight Loss Trial & Old Systematic Reviews
It just seems logical, doesn’t it? Super-sizing your food can super-size you. So when I used to see claims that a bigger plate = a bigger you, it made sense. But then a
It started in June, with cardiovascular disease. Then August ended with another bout, but in cancer. It’s been a rough few months for non-inferiority clinical trials! We’ve known for as long as there
A Classic Case of Science “He Said”, “She Said”: How Psychologists Trying to Prevent PTSD Got Controversial
Natural disasters have a lot in common with other major traumas, like life-threatening accidents and mass shootings – especially the emotional distress they leave in their aftermath. As predictable and common as
Sometimes, a dispute with a consumer movement comes along that has profound implications for far more than the people in it. I think the dramatic clash between the ME/CFS patient community and a
A study piqued my curiosity in a news feed recently. Yoga could reduce depression symptoms, researchers said – but only if you expected it to (Uebelacker 2018). Yoga for depression, it turns out, is
A very influential nutrition trial just tanked. It was retracted from the New England Journal of Medicine (NEJM) on 13 June, and re-published with new analyses and toned-down conclusions. Both Gina Kolata, writing in
“I remember wheeling down this long, narrow corridor into my office, just a confused, scared mess, but I had to confront him.” Phil Vardy was a young medical researcher in Sydney that day in 1982. The
The case of the missing neurological drug trials remains shrouded in mystery. Nearly 48,000 people took part in these trials for new drugs for multiple sclerosis, stroke, Alzheimer disease, migraine, epilepsy, insomnia, and Parkinson disease.
A tweet jolted me today. Doublespeak hit the news a few days ago, sending George Orwell’s final masterpiece, Nineteen Eighty-Four, back into a bestseller list. It was the anniversary of Orwell’s death this weekend, too.